| Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature A Saber, TJN Hiltermann, K Kok, HJM Groen Critical reviews in oncology/hematology 100, 107-116, 2016 | 113 | 2016 |
| The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing Y Liu, FR Abdul Razak, M Terpstra, FC Chan, A Saber, M Nijland, ... Leukemia 28 (11), 2248-2251, 2014 | 103 | 2014 |
| CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment B Liu, A Saber, HJ Haisma Drug discovery today 24 (4), 955-970, 2019 | 75 | 2019 |
| Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers J Wei, AJ Van der Wekken, A Saber, MM Terpstra, E Schuuring, W Timens, ... Cancers 10 (1), 10, 2018 | 40 | 2018 |
| Mutation patterns in small cell and non-small cell lung cancer patients suggest a different level of heterogeneity between primary and metastatic tumors A Saber, TJN Hiltermann, K Kok, MM Terpstra, K de Lange, W Timens, ... Carcinogenesis 38 (2), 144-151, 2017 | 39 | 2017 |
| CX Chemokine Receptor 7 Contributes to Survival of KRAS-Mutant Non-Small Cell Lung Cancer upon Loss of Epidermal Growth Factor Receptor B Liu, S Song, R Setroikromo, S Chen, W Hu, D Chen, AJ van der Wekken, ... Cancers 11 (4), 455, 2019 | 34 | 2019 |
| Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression AJ van der Wekken, JL Kuiper, A Saber, MM Terpstra, J Wei, ... PloS one 12 (8), e0182885, 2017 | 30 | 2017 |
| Genomic aberrations guiding treatment of non-small cell lung cancer patients A Saber, A van der Wekken, TJN Hiltermann, K Kok, A van den Berg, ... Cancer Treatment Communications 4, 23-33, 2015 | 30 | 2015 |
| Cancer driver gene and non-coding RNA alterations as biomarkers of brain metastasis in lung cancer: a review of the literature M Karimpour, R Ravanbakhsh, M Maydanchi, A Rajabi, F Azizi, A Saber Biomedicine & Pharmacotherapy 143, 112190, 2021 | 27 | 2021 |
| CRISPR/Cas9 for overcoming drug resistance in solid tumors A Saber, B Liu, P Ebrahimi, HJ Haisma DARU Journal of Pharmaceutical Sciences 28, 295-304, 2020 | 25 | 2020 |
| Copy number alterations assessed at the single-cell level revealed mono-and polyclonal seeding patterns of distant metastasis in a small-cell lung cancer patient P Ferronika, H Van Den Bos, A Taudt, DCJ Spierings, A Saber, ... Annals of Oncology 28 (7), 1668-1670, 2017 | 25 | 2017 |
| Genomic aberrations in crizotinib resistant lung adenocarcinoma samples identified by transcriptome sequencing A Saber, AJ van der Wekken, K Kok, MM Terpstra, LJ Bosman, MF Mastik, ... PLoS One 11 (4), e0153065, 2016 | 21 | 2016 |
| CRISPR-mediated ablation of overexpressed EGFR in combination with sunitinib significantly suppresses renal cell carcinoma proliferation B Liu, OA Diaz Arguello, D Chen, S Chen, A Saber, HJ Haisma Plos one 15 (5), e0232985, 2020 | 19 | 2020 |
| Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer B Liu, D Chen, S Chen, A Saber, H Haisma Biochemical Pharmacology 178, 114095, 2020 | 17 | 2020 |
| Moderate prognostic value of lncRNA FOXD2-AS1 in gastric cancer with Helicobacter pylori infection A Rajabi, S Bastani, M Maydanchi, S Tayefeh-Gholami, S Abdolahi, ... Journal of Gastrointestinal Cancer, 1-5, 2021 | 16 | 2021 |
| Chronic Obstructive Pulmonary Disease Is Not Associated with KRAS Mutations in Non-Small Cell Lung Cancer A Saber, AJ van der Wekken, GSMA Kerner, M van den Berge, W Timens, ... PLoS One 11 (3), e0152317, 2016 | 13 | 2016 |
| Prognostic value of lncRNA KRT18P55 in patients with intestinal type of gastric cancer S Tayefeh-Gholami, M Ghanbari, A Aghazadeh, A Rajabi, A Saber, ... Journal of Gastrointestinal Cancer, 1-6, 2021 | 8 | 2021 |
| Anti-cancer effect of melatonin via downregulation of Delta-like ligand 4 in Estrogen-responsive breast cancer cells A Rajabi, A Saber, M Pourmahdi, A Emami, R Ravanbakhsh, ... Recent Patents on Anti-Cancer Drug Discovery 15 (4), 329-340, 2020 | 8 | 2020 |
| An all-in-one transcriptome-based assay to identify therapy-guiding genomic aberrations in nonsmall cell lung cancer patients J Wei, AA Rybczynska, P Meng, M Terpstra, A Saber, J Sietzema, ... Cancers 12 (10), 2843, 2020 | 7 | 2020 |
| Key Epigenetic Events Involved in the Maintenance of Breast Cancer Stem Cells M Pourmahdi, A Saber, A Rajabi, S Abdolahi, P Ebrahimi, ... Curr. Stem Cell Res. Ther 16, 877-887, 2021 | 4 | 2021 |
Anke van den BergProfessor of Molecular biology of malignant B cell lymphomas, University of Groningen, UniversityVerified email at umcg.nl
